As treatment continues, appetite regulation in the brain becomes more stable
V.TanrioeverG.KnigJ.RothS.et al (2020)
This material is not a drug, supplement, cosmetic, or food, and is not for human or veterinary use, injection, or ingestion
Phase Maintenance Weeks 25+ Tirzepatide 15.0 mg/week Cagrilintide 2.4 mg/week Notes Full 3-receptor coverage if tolerated
Both semaglutide and tirzepatide have shown promising results for weight loss
GLP-1s may additionally impact other physiological changes observed in the perimenopausal period, including vasomotor symptoms like hot flashes and night sweats, declines in bone health, and unhealthy changes in body composition (gains in fat mass and declines in muscle mass), but whether these impacts are beneficial or harmful for women's health remains unknown